As inclusion criteria, AD donors with only amyloid-β pathology (no tauopathy yet) in the occipital cortex (OC) and both amyloid-β and tau pathology in the occipitotemporal cortex (OTC) were selected for this study. The gene discussed is MAPT; the disease is Alzheimer disease.